<VariationArchive VariationID="15938" VariationName="NM_000516.7(GNAS):c.565_568del (p.Asp189fs)" VariationType="Deletion" Accession="VCV000015938" Version="21" RecordType="classified" NumberOfSubmissions="16" NumberOfSubmitters="14" DateLastUpdated="2024-07-29" DateCreated="2017-09-30" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="30977" VariationID="15938">
      <GeneList>
        <Gene Symbol="GNAS" FullName="GNAS complex locus" GeneID="2778" HGNC_ID="HGNC:4392" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q13.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58839748" stop="58911192" display_start="58839748" display_stop="58911192" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57414794" stop="57486249" display_start="57414794" display_stop="57486249" Strand="+" />
          </Location>
          <OMIM>139320</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000516.7(GNAS):c.565_568del (p.Asp189fs)</Name>
      <CanonicalSPDI>NC_000020.11:58909193:CTGACT:CT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>20q13.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58909194" stop="58909197" display_start="58909194" display_stop="58909197" variantLength="4" positionVCF="58909193" referenceAlleleVCF="GCTGA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57484249" stop="57484252" display_start="57484249" display_stop="57484252" variantLength="4" positionVCF="57484248" referenceAlleleVCF="GCTGA" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>D189MfsX14</Name>
      </OtherNameList>
      <ProteinChange>D130fs</ProteinChange>
      <ProteinChange>D174fs</ProteinChange>
      <ProteinChange>D175fs</ProteinChange>
      <ProteinChange>D189fs</ProteinChange>
      <ProteinChange>D190fs</ProteinChange>
      <ProteinChange>D832fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.57484251_57484254del" Assembly="GRCh37">
            <Expression>NC_000020.10:g.57484251_57484254del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.58909196_58909199del" Assembly="GRCh38">
            <Expression>NC_000020.11:g.58909196_58909199del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_016194.2" sequenceAccession="NG_016194" sequenceVersion="2" change="g.74457_74460del">
            <Expression>NG_016194.2:g.74457_74460del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.7" sequenceAccession="NM_000516" sequenceVersion="7" change="c.565_568del" MANESelect="true">
            <Expression>NM_000516.7:c.565_568del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000507.1" sequenceAccession="NP_000507" sequenceVersion="1" change="p.Asp189fs">
            <Expression>NP_000507.1:p.Asp189fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077488.5" sequenceAccession="NM_001077488" sequenceVersion="5" change="c.568_571del">
            <Expression>NM_001077488.5:c.568_571del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070956.1" sequenceAccession="NP_001070956" sequenceVersion="1" change="p.Asp190fs">
            <Expression>NP_001070956.1:p.Asp190fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077489.4" sequenceAccession="NM_001077489" sequenceVersion="4" change="c.520_523del">
            <Expression>NM_001077489.4:c.520_523del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070957.1" sequenceAccession="NP_001070957" sequenceVersion="1" change="p.Asp174fs">
            <Expression>NP_001070957.1:p.Asp174fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077490.3" sequenceAccession="NM_001077490" sequenceVersion="3" change="c.*426_*429del">
            <Expression>NM_001077490.3:c.*426_*429del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309840.2" sequenceAccession="NM_001309840" sequenceVersion="2" change="c.388_391del">
            <Expression>NM_001309840.2:c.388_391del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001296769.1" sequenceAccession="NP_001296769" sequenceVersion="1" change="p.Asp130fs">
            <Expression>NP_001296769.1:p.Asp130fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309861.2" sequenceAccession="NM_001309861" sequenceVersion="2" change="c.388_391del">
            <Expression>NM_001309861.2:c.388_391del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001296790.1" sequenceAccession="NP_001296790" sequenceVersion="1" change="p.Asp130fs">
            <Expression>NP_001296790.1:p.Asp130fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016592.5" sequenceAccession="NM_016592" sequenceVersion="5" change="c.*471_*474del" MANEPlusClinical="true">
            <Expression>NM_016592.5:c.*471_*474del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080425.4" sequenceAccession="NM_080425" sequenceVersion="4" change="c.2494_2497del" MANEPlusClinical="true">
            <Expression>NM_080425.4:c.2494_2497del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_536350.2" sequenceAccession="NP_536350" sequenceVersion="2" change="p.Asp832fs">
            <Expression>NP_536350.2:p.Asp832fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080426.4" sequenceAccession="NM_080426" sequenceVersion="4" change="c.523_526del">
            <Expression>NM_080426.4:c.523_526del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_536351.1" sequenceAccession="NP_536351" sequenceVersion="1" change="p.Asp175fs">
            <Expression>NP_536351.1:p.Asp175fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.7" sequenceAccession="NM_000516" sequenceVersion="7" change="c.563_566del" MANESelect="true">
            <Expression>NM_000516.7:c.563_566del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.4" sequenceAccession="NM_000516" sequenceVersion="4" change="c.565_568delGACT">
            <Expression>NM_000516.4:c.565_568delGACT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA126088" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="139320.0011" DB="OMIM" />
        <XRef Type="rs" ID="587776829" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 1505964 Fig. 2 to determine the location of this allele on the current reference sequence.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Pseudohypoparathyroidism" Accession="RCV000017300" Version="37">
        <ClassifiedConditionList TraitSetID="5179">
          <ClassifiedCondition DB="MedGen" ID="C0033806">Pseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-10-01" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Progressive osseous heteroplasia" Accession="RCV000017301" Version="40">
        <ClassifiedConditionList TraitSetID="5181">
          <ClassifiedCondition DB="MedGen" ID="C0334041">Progressive osseous heteroplasia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2008-07-15" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Pseudopseudohypoparathyroidism" Accession="RCV000017302" Version="39">
        <ClassifiedConditionList TraitSetID="5180">
          <ClassifiedCondition DB="MedGen" ID="C0033835">Pseudopseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2008-07-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND not specified" Accession="RCV000678707" Version="9">
        <ClassifiedConditionList TraitSetID="9590">
          <ClassifiedCondition DB="MedGen" ID="CN169374">not specified</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-12-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Pseudohypoparathyroidism type 1B" Accession="RCV001196108" Version="11">
        <ClassifiedConditionList TraitSetID="321">
          <ClassifiedCondition DB="MedGen" ID="C1864100">Pseudohypoparathyroidism type 1B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
            <Description DateLastEvaluated="2024-04-04" SubmissionCount="2">Conflicting interpretations of pathogenicity</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Pseudohypoparathyroidism type I A" Accession="RCV001731307" Version="9">
        <ClassifiedConditionList TraitSetID="66069">
          <ClassifiedCondition DB="MedGen" ID="C3494506">Pseudohypoparathyroidism type I A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND not provided" Accession="RCV001851884" Version="13">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-12-27" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND multiple conditions" Accession="RCV002496387" Version="8">
        <ClassifiedConditionList TraitSetID="69445">
          <ClassifiedCondition DB="MedGen" ID="C1857451">ACTH-independent macronodular adrenal hyperplasia 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0242292">McCune-Albright syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4540135">Pituitary adenoma 3, multiple types</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0334041">Progressive osseous heteroplasia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1864100">Pseudohypoparathyroidism type 1B</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2932716">Pseudohypoparathyroidism type 1C</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3494506">Pseudohypoparathyroidism type I A</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0033835">Pseudopseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Inborn genetic diseases" Accession="RCV003162254" Version="9">
        <ClassifiedConditionList TraitSetID="25797">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND Disorders of GNAS Inactivation" Accession="RCV003389234" Version="1">
        <ClassifiedConditionList TraitSetID="88897">
          <ClassifiedCondition>Disorders of GNAS Inactivation</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-08-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND multiple conditions" Accession="RCV003227604" Version="8">
        <ClassifiedConditionList TraitSetID="74974">
          <ClassifiedCondition DB="MedGen" ID="C0334041">Progressive osseous heteroplasia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1864100">Pseudohypoparathyroidism type 1B</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2932716">Pseudohypoparathyroidism type 1C</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3494506">Pseudohypoparathyroidism type I A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.565_568del (p.Asp189fs) AND GNAS-related disorder" Accession="RCV004532373" Version="1">
        <ClassifiedConditionList TraitSetID="47071">
          <ClassifiedCondition>GNAS-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-04-04" NumberOfSubmissions="16" NumberOfSubmitters="14" DateCreated="2017-09-30" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
        <Description>Conflicting classifications of pathogenicity</Description>
        <Explanation DataSource="ClinVar" Type="public">Pathogenic(11); Uncertain significance(1)</Explanation>
        <Citation Type="general">
          <ID Source="PubMed">11784876</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12024004</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1505964</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15711092</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18553568</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20427508</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23281139</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23796510</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24481334</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24626099</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25219572</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25802881</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29059381</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30674755</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30729047</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31793173</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31886927</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34254228</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34418133</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34614324</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35296306</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35357904</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35497370</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9876352</ID>
        </Citation>
        <Comment DataSource="ClinVar" Type="public">Pathogenic(11); Uncertain significance(1)</Comment>
        <DescriptionHistory Dated="2024-04-11">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="5179" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3403" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism</ElementValue>
                <XRef ID="HP:0000852" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0019992" DB="MONDO" />
                <XRef ID="58976002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10758" />
                <XRef ID="10758" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="97593" DB="Orphanet" />
              <XRef ID="C0033806" DB="MedGen" />
              <XRef ID="MONDO:0019992" DB="MONDO" />
              <XRef Type="primary" ID="HP:0000852" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="5180" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="4060" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy without multiple hormone resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudopseudohypoparathyroidism</ElementValue>
                <XRef ID="Pseudopseudohypoparathyroidism/6049" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012912" DB="MONDO" />
                <XRef ID="237659007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPHP</ElementValue>
                <XRef Type="MIM" ID="612463" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7860" />
                <XRef ID="7860" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79445" DB="Orphanet" />
              <XRef ID="C0033835" DB="MedGen" />
              <XRef ID="MONDO:0012912" DB="MONDO" />
              <XRef Type="MIM" ID="612463" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="5181" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5691" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ECTOPIC OSSIFICATION, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Osseus Heteroplasia, Progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive osseous heteroplasia</ElementValue>
                <XRef ID="Progressive+osseous+heteroplasia/5985" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008153" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">POH</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="109" />
                <XRef ID="109" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="2762" DB="Orphanet" />
              <XRef ID="C0334041" DB="MedGen" />
              <XRef ID="MONDO:0008153" DB="MONDO" />
              <XRef Type="MIM" ID="166350" DB="OMIM" />
              <XRef Type="primary" ID="HP:0025027" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="321" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4057" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1B</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1B/6036" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011301" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IB</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1B</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10680" />
                <XRef ID="10680" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="94089" DB="Orphanet" />
              <XRef ID="C1864100" DB="MedGen" />
              <XRef ID="MONDO:0011301" DB="MONDO" />
              <XRef Type="MIM" ID="603233" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="69445" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4057" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1B</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1B/6036" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011301" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IB</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1B</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10680" />
                <XRef ID="10680" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="94089" DB="Orphanet" />
              <XRef ID="C1864100" DB="MedGen" />
              <XRef ID="MONDO:0011301" DB="MONDO" />
              <XRef Type="MIM" ID="603233" DB="OMIM" />
            </Trait>
            <Trait ID="4060" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy without multiple hormone resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudopseudohypoparathyroidism</ElementValue>
                <XRef ID="Pseudopseudohypoparathyroidism/6049" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012912" DB="MONDO" />
                <XRef ID="237659007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPHP</ElementValue>
                <XRef Type="MIM" ID="612463" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7860" />
                <XRef ID="7860" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79445" DB="Orphanet" />
              <XRef ID="C0033835" DB="MedGen" />
              <XRef ID="MONDO:0012912" DB="MONDO" />
              <XRef Type="MIM" ID="612463" DB="OMIM" />
            </Trait>
            <Trait ID="38135" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PITUITARY ADENOMA 3, ACTH-SECRETING, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="139320.0012" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PITUITARY ADENOMA 3, GROWTH HORMONE-SECRETING, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="139320.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0009" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pituitary adenoma 3, multiple types</ElementValue>
                <XRef ID="MONDO:0054665" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PITA3</ElementValue>
                <XRef Type="MIM" ID="617686" DB="OMIM" />
              </Symbol>
              <XRef ID="C4540135" DB="MedGen" />
              <XRef ID="MONDO:0054665" DB="MONDO" />
              <XRef Type="MIM" ID="617686" DB="OMIM" />
            </Trait>
            <Trait ID="56041" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IA</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy with multiple hormone resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism type 1A</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1A/6035" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007078" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IA</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type I A</ElementValue>
                <XRef ID="58833000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7486" />
                <XRef ID="7486" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="C3494506" DB="MedGen" />
              <XRef ID="MONDO:0007078" DB="MONDO" />
              <XRef Type="MIM" ID="103580" DB="OMIM" />
            </Trait>
            <Trait ID="3404" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PSEUDOHYPOPARATHYROIDISM, TYPE IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0039" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0038" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0036" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0040" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1C</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1C/6037" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012911" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1C</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10681" />
                <XRef ID="10681" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79444" DB="Orphanet" />
              <XRef ID="C2932716" DB="MedGen" />
              <XRef ID="MONDO:0012911" DB="MONDO" />
              <XRef Type="MIM" ID="612462" DB="OMIM" />
            </Trait>
            <Trait ID="2828" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">McCune-Albright syndrome, somatic, mosaic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright's Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">McCune-Albright syndrome</ElementValue>
                <XRef ID="McCune+Albright+syndrome/4524" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018919" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright's disease</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MAS</ElementValue>
                <XRef Type="MIM" ID="174800" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PFD</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">POFD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fibrous dysplasia / McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating pathogenic variant in GNAS (encoding the cAMP pathway-associated G-protein, Gsα), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because Gsα signaling is ubiquitous, additional tissues may be affected. Café au lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. Fibrous dysplasia (FD), which can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton, can range from an isolated, asymptomatic monostotic lesion discovered incidentally to severe disabling polyostotic disease involving practically the entire skeleton and leading to progressive scoliosis, facial deformity, and loss of mobility, vision, and/or hearing. Endocrinopathies include: Gonadotropin-independent precocious puberty resulting from recurrent ovarian cysts in girls and autonomous testosterone production in boys; Testicular lesions with or without associated gonadotropin-independent precocious puberty; Thyroid lesions with or without non-autoimmune hyperthyroidism; Growth hormone excess; FGF23-mediated phosphate wasting with or without hypophosphatemia in association with fibrous dysplasia; and Neonatal hypercortisolism. The prognosis for individuals with FD/MAS is based on disease location and severity.</Attribute>
                <XRef ID="NBK274564" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6995" />
                <XRef ID="6995" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25719192</ID>
                <ID Source="BookShelf">NBK274564</ID>
              </Citation>
              <Citation Type="review" Abbrev="Medical Genetics Summaries">
                <ID Source="BookShelf">NBK66130</ID>
              </Citation>
              <XRef ID="562" DB="Orphanet" />
              <XRef ID="C0242292" DB="MedGen" />
              <XRef ID="MONDO:0018919" DB="MONDO" />
              <XRef Type="MIM" ID="174800" DB="OMIM" />
            </Trait>
            <Trait ID="56005" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACTH-INDEPENDENT MACRONODULAR ADRENOCORTICAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CORTICOTROPIN-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">ACTH-independent macronodular adrenal hyperplasia 1</ElementValue>
                <XRef ID="MONDO:0020735" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CUSHING SYNDROME, ADRENAL, DUE TO AIMAH</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACTH-independent macronodular adrenal hyperplasia, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ADRENOCORTICOTROPIC HORMONE-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">AIMAH1</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Symbol>
              <XRef ID="C1857451" DB="MedGen" />
              <XRef ID="MONDO:0020735" DB="MONDO" />
              <XRef Type="MIM" ID="219080" DB="OMIM" />
            </Trait>
            <Trait ID="5691" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ECTOPIC OSSIFICATION, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Osseus Heteroplasia, Progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive osseous heteroplasia</ElementValue>
                <XRef ID="Progressive+osseous+heteroplasia/5985" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008153" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">POH</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="109" />
                <XRef ID="109" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="2762" DB="Orphanet" />
              <XRef ID="C0334041" DB="MedGen" />
              <XRef ID="MONDO:0008153" DB="MONDO" />
              <XRef Type="MIM" ID="166350" DB="OMIM" />
              <XRef Type="primary" ID="HP:0025027" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="66069" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="56041" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IA</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy with multiple hormone resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism type 1A</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1A/6035" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007078" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IA</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type I A</ElementValue>
                <XRef ID="58833000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7486" />
                <XRef ID="7486" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="C3494506" DB="MedGen" />
              <XRef ID="MONDO:0007078" DB="MONDO" />
              <XRef Type="MIM" ID="103580" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="88897" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="69110" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Disorders of GNAS Inactivation</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="74974" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4057" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1B</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1B/6036" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011301" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IB</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1B</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10680" />
                <XRef ID="10680" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="94089" DB="Orphanet" />
              <XRef ID="C1864100" DB="MedGen" />
              <XRef ID="MONDO:0011301" DB="MONDO" />
              <XRef Type="MIM" ID="603233" DB="OMIM" />
            </Trait>
            <Trait ID="56041" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IA</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy with multiple hormone resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism type 1A</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1A/6035" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007078" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IA</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type I A</ElementValue>
                <XRef ID="58833000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7486" />
                <XRef ID="7486" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="C3494506" DB="MedGen" />
              <XRef ID="MONDO:0007078" DB="MONDO" />
              <XRef Type="MIM" ID="103580" DB="OMIM" />
            </Trait>
            <Trait ID="3404" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PSEUDOHYPOPARATHYROIDISM, TYPE IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0039" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0038" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0036" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0040" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1C</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1C/6037" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012911" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1C</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10681" />
                <XRef ID="10681" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79444" DB="Orphanet" />
              <XRef ID="C2932716" DB="MedGen" />
              <XRef ID="MONDO:0012911" DB="MONDO" />
              <XRef Type="MIM" ID="612462" DB="OMIM" />
            </Trait>
            <Trait ID="5691" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ECTOPIC OSSIFICATION, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Osseus Heteroplasia, Progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive osseous heteroplasia</ElementValue>
                <XRef ID="Progressive+osseous+heteroplasia/5985" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008153" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">POH</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="109" />
                <XRef ID="109" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="2762" DB="Orphanet" />
              <XRef ID="C0334041" DB="MedGen" />
              <XRef ID="MONDO:0008153" DB="MONDO" />
              <XRef Type="MIM" ID="166350" DB="OMIM" />
              <XRef Type="primary" ID="HP:0025027" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="47071" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="41586" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GNAS-related disorder</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25797" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9590" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16789" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not specified</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AllHighlyPenetrant</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not specified' was created for use in ClinVar so that submitters can convey the concept that a variant is benign, likely benign, or of uncertain significance for an unspecified set of disorders.  This usage was introduced in 2014 to replace AllHighlyPenetrant.</Attribute>
              </AttributeSet>
              <XRef ID="CN169374" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="37572" SubmissionDate="2017-09-26" DateLastUpdated="2017-09-30" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="139320.0011_PSEUDOHYPOPARATHYROIDISM, TYPE IA" title="GNAS, 4-BP DEL, 565CTGA_PSEUDOHYPOPARATHYROIDISM, TYPE IA" />
        <ClinVarAccession Accession="SCV000037572" DateUpdated="2017-09-30" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-07-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in a frameshift and premature stop codon. Analysis of lymphocyte RNA by reverse transcription-PCR and direct sequencing showed that the GNAS1 allele bearing the mutation was not expressed as mRNA. Consistent with this, Northern blot analysis revealed an approximately 50% deficiency in steady-state levels of GNAS1 mRNA.</Attribute>
              <Citation>
                <ID Source="PubMed">1505964</ID>
              </Citation>
              <XRef DB="OMIM" ID="103580" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ahmed et al. (1998) identified this deletion mutation in 2 unrelated families with PHP Ia.</Attribute>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Shore et al. (2002) provided direct evidence that the 4-bp deletion can cause either progressive osseous heteroplasia (POH; 166350) or Albright hereditary osteodystrophy without hormone resistance (PPHP; 612463) in the same family. Five sisters with POH had inherited this mutation from the father in whom the mutation was nonpenetrant. Three offspring of these sisters had AHO, including traces of subcutaneous ossification. Shore et al. (2002) suggested that POH requires paternal inheritance of a GNAS1 mutation, whereas hormone resistance is more likely to occur when the genetic defect is maternally inherited.</Attribute>
              <Citation>
                <ID Source="PubMed">11784876</ID>
              </Citation>
              <Citation>
                <CitationText>Shore, E. M., Kaplan, F. S., Levine, M. A. GNAS1 mutations and progressive osseous heteroplasia. (Letter) New Eng. J. Med. 346: 1670-1671, 2002.</CitationText>
              </Citation>
              <XRef DB="OMIM" ID="166350" Type="MIM" />
              <XRef DB="OMIM" ID="612463" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ahmed et al. (2002) cautioned against a premature conclusion that POH may require paternal inheritance. In a family reported by Ahmed et al. (1998), the 4-bp deletion was found in a brother and sister and in their mother but not in their father. Aside from brachymetacarpia and short stature, the mother did not have features of AHO. The daughter had typical features of AHO and hormone resistant PHP1A; in contrast, her brother presented in the first year of life with ossification of subcutaneous tissue that was followed by progressive, generalized heterotopic ossification of skeletal muscle, without any clear evidence of hormone resistance. These cases exemplified the wide phenotypic heterogeneity in persons with mutations in GNAS1, even within 1 family.</Attribute>
              <Citation>
                <ID Source="PubMed">12024004</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Bastepe and Juppner (2002) suggested that, like some patients who have either PHP type Ia or PHP type Ib, the son described by Ahmed et al. (1998) may have developed resistance to parathyroid hormone later in life or not at all. Given that the patient's sister and mother had PHP type Ia and PPHP, respectively, POH resulting from maternally inherited GNAS1 mutations may actually represent an incomplete form of PHP type Ia. Bastepe and Juppner (2002) suggested that the underlying mechanism for this form of POH may be distinct from that described by Shore et al. (2002), which appears to result only from paternally inherited GNAS1 mutations.</Attribute>
              <Citation>
                <ID Source="PubMed">15711092</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">11784876</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Adegbite et al. (2008) identified heterozygosity for the 565delCTGA mutation in the GNAS gene in 13 POH cases (10 familial cases among 3 different families, and 3 individual spontaneous cases). The mutation resulted in variable severity and pleiotropy, both in family members and in unrelated sporadic cases.</Attribute>
              <Citation>
                <ID Source="PubMed">18553568</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <Name>GNAS, 4-BP DEL, 565CTGA</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 565CTGA</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="139320.0011" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PSEUDOHYPOPARATHYROIDISM, TYPE IA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="37573" SubmissionDate="2017-09-26" DateLastUpdated="2017-09-30" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="139320.0011_OSSEOUS HETEROPLASIA, PROGRESSIVE" title="GNAS, 4-BP DEL, 565CTGA_OSSEOUS HETEROPLASIA, PROGRESSIVE" />
        <ClinVarAccession Accession="SCV000037573" DateUpdated="2017-09-30" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-07-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in a frameshift and premature stop codon. Analysis of lymphocyte RNA by reverse transcription-PCR and direct sequencing showed that the GNAS1 allele bearing the mutation was not expressed as mRNA. Consistent with this, Northern blot analysis revealed an approximately 50% deficiency in steady-state levels of GNAS1 mRNA.</Attribute>
              <Citation>
                <ID Source="PubMed">1505964</ID>
              </Citation>
              <XRef DB="OMIM" ID="103580" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ahmed et al. (1998) identified this deletion mutation in 2 unrelated families with PHP Ia.</Attribute>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Shore et al. (2002) provided direct evidence that the 4-bp deletion can cause either progressive osseous heteroplasia (POH; 166350) or Albright hereditary osteodystrophy without hormone resistance (PPHP; 612463) in the same family. Five sisters with POH had inherited this mutation from the father in whom the mutation was nonpenetrant. Three offspring of these sisters had AHO, including traces of subcutaneous ossification. Shore et al. (2002) suggested that POH requires paternal inheritance of a GNAS1 mutation, whereas hormone resistance is more likely to occur when the genetic defect is maternally inherited.</Attribute>
              <Citation>
                <ID Source="PubMed">11784876</ID>
              </Citation>
              <Citation>
                <CitationText>Shore, E. M., Kaplan, F. S., Levine, M. A. GNAS1 mutations and progressive osseous heteroplasia. (Letter) New Eng. J. Med. 346: 1670-1671, 2002.</CitationText>
              </Citation>
              <XRef DB="OMIM" ID="166350" Type="MIM" />
              <XRef DB="OMIM" ID="612463" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ahmed et al. (2002) cautioned against a premature conclusion that POH may require paternal inheritance. In a family reported by Ahmed et al. (1998), the 4-bp deletion was found in a brother and sister and in their mother but not in their father. Aside from brachymetacarpia and short stature, the mother did not have features of AHO. The daughter had typical features of AHO and hormone resistant PHP1A; in contrast, her brother presented in the first year of life with ossification of subcutaneous tissue that was followed by progressive, generalized heterotopic ossification of skeletal muscle, without any clear evidence of hormone resistance. These cases exemplified the wide phenotypic heterogeneity in persons with mutations in GNAS1, even within 1 family.</Attribute>
              <Citation>
                <ID Source="PubMed">12024004</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Bastepe and Juppner (2002) suggested that, like some patients who have either PHP type Ia or PHP type Ib, the son described by Ahmed et al. (1998) may have developed resistance to parathyroid hormone later in life or not at all. Given that the patient's sister and mother had PHP type Ia and PPHP, respectively, POH resulting from maternally inherited GNAS1 mutations may actually represent an incomplete form of PHP type Ia. Bastepe and Juppner (2002) suggested that the underlying mechanism for this form of POH may be distinct from that described by Shore et al. (2002), which appears to result only from paternally inherited GNAS1 mutations.</Attribute>
              <Citation>
                <ID Source="PubMed">15711092</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">11784876</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Adegbite et al. (2008) identified heterozygosity for the 565delCTGA mutation in the GNAS gene in 13 POH cases (10 familial cases among 3 different families, and 3 individual spontaneous cases). The mutation resulted in variable severity and pleiotropy, both in family members and in unrelated sporadic cases.</Attribute>
              <Citation>
                <ID Source="PubMed">18553568</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <Name>GNAS, 4-BP DEL, 565CTGA</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 565CTGA</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="139320.0011" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">OSSEOUS HETEROPLASIA, PROGRESSIVE</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="37574" SubmissionDate="2017-09-26" DateLastUpdated="2017-09-30" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="139320.0011_PSEUDOPSEUDOHYPOPARATHYROIDISM" title="GNAS, 4-BP DEL, 565CTGA_PSEUDOPSEUDOHYPOPARATHYROIDISM" />
        <ClinVarAccession Accession="SCV000037574" DateUpdated="2017-09-30" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-07-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in a frameshift and premature stop codon. Analysis of lymphocyte RNA by reverse transcription-PCR and direct sequencing showed that the GNAS1 allele bearing the mutation was not expressed as mRNA. Consistent with this, Northern blot analysis revealed an approximately 50% deficiency in steady-state levels of GNAS1 mRNA.</Attribute>
              <Citation>
                <ID Source="PubMed">1505964</ID>
              </Citation>
              <XRef DB="OMIM" ID="103580" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ahmed et al. (1998) identified this deletion mutation in 2 unrelated families with PHP Ia.</Attribute>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Shore et al. (2002) provided direct evidence that the 4-bp deletion can cause either progressive osseous heteroplasia (POH; 166350) or Albright hereditary osteodystrophy without hormone resistance (PPHP; 612463) in the same family. Five sisters with POH had inherited this mutation from the father in whom the mutation was nonpenetrant. Three offspring of these sisters had AHO, including traces of subcutaneous ossification. Shore et al. (2002) suggested that POH requires paternal inheritance of a GNAS1 mutation, whereas hormone resistance is more likely to occur when the genetic defect is maternally inherited.</Attribute>
              <Citation>
                <ID Source="PubMed">11784876</ID>
              </Citation>
              <Citation>
                <CitationText>Shore, E. M., Kaplan, F. S., Levine, M. A. GNAS1 mutations and progressive osseous heteroplasia. (Letter) New Eng. J. Med. 346: 1670-1671, 2002.</CitationText>
              </Citation>
              <XRef DB="OMIM" ID="166350" Type="MIM" />
              <XRef DB="OMIM" ID="612463" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ahmed et al. (2002) cautioned against a premature conclusion that POH may require paternal inheritance. In a family reported by Ahmed et al. (1998), the 4-bp deletion was found in a brother and sister and in their mother but not in their father. Aside from brachymetacarpia and short stature, the mother did not have features of AHO. The daughter had typical features of AHO and hormone resistant PHP1A; in contrast, her brother presented in the first year of life with ossification of subcutaneous tissue that was followed by progressive, generalized heterotopic ossification of skeletal muscle, without any clear evidence of hormone resistance. These cases exemplified the wide phenotypic heterogeneity in persons with mutations in GNAS1, even within 1 family.</Attribute>
              <Citation>
                <ID Source="PubMed">12024004</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Bastepe and Juppner (2002) suggested that, like some patients who have either PHP type Ia or PHP type Ib, the son described by Ahmed et al. (1998) may have developed resistance to parathyroid hormone later in life or not at all. Given that the patient's sister and mother had PHP type Ia and PPHP, respectively, POH resulting from maternally inherited GNAS1 mutations may actually represent an incomplete form of PHP type Ia. Bastepe and Juppner (2002) suggested that the underlying mechanism for this form of POH may be distinct from that described by Shore et al. (2002), which appears to result only from paternally inherited GNAS1 mutations.</Attribute>
              <Citation>
                <ID Source="PubMed">15711092</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9876352</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">11784876</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Adegbite et al. (2008) identified heterozygosity for the 565delCTGA mutation in the GNAS gene in 13 POH cases (10 familial cases among 3 different families, and 3 individual spontaneous cases). The mutation resulted in variable severity and pleiotropy, both in family members and in unrelated sporadic cases.</Attribute>
              <Citation>
                <ID Source="PubMed">18553568</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <Name>GNAS, 4-BP DEL, 565CTGA</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 565CTGA</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="139320.0011" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">PSEUDOPSEUDOHYPOPARATHYROIDISM</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1569752" SubmissionDate="2018-07-17" DateLastUpdated="2018-09-14" DateCreated="2018-09-14">
        <ClinVarSubmissionID localKey="NM_000516.5:c.565_568delGACT|not specified" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000804871" DateUpdated="2018-09-14" DateCreated="2018-09-14" Type="SCV" Version="1" SubmitterName="Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital" OrgID="1027" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-12-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.5:c.565_568delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not specified</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4286518</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1945579" SubmissionDate="2019-11-14" DateLastUpdated="2020-03-07" DateCreated="2019-09-11">
        <ClinVarSubmissionID localKey="NM_000516.5:c.565_568delGACT|OMIM:103580" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000992358" DateUpdated="2020-03-07" DateCreated="2019-09-11" Type="SCV" Version="2" SubmitterName="Johns Hopkins Genomics, Johns Hopkins University" OrgID="506823" OrganizationCategory="laboratory" OrgAbbreviation="JHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-10-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000516.5:exon 7</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.5:c.565_568delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6546915</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3099413" SubmissionDate="2021-05-07" DateLastUpdated="2021-10-30" DateCreated="2021-10-30">
        <ClinVarSubmissionID localKey="NM_000516.7:c.563_566del|OMIM:103580" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001573812" DateUpdated="2021-10-30" DateCreated="2021-10-30" Type="SCV" Version="1" SubmitterName="Genetics of Obesity Study, University of Cambridge" OrgID="508071" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-06-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">34614324</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>de novo</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>D189MfsX14</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.7:c.563_566del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">34614324</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34614324</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB9598829</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5457220" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000516.7:c.565_568del|OMIM:103580;166350;174800;219080;603233;612462;612463;617686" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002806191" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.7:c.565_568del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="166350" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="174800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219080" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612462" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612463" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617686" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4890417" SubmissionDate="2022-04-20" DateLastUpdated="2023-03-04" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="GDXSV:225026" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002499789" DateUpdated="2023-03-04" DateCreated="2022-04-23" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Reported as a common pathogenic variant in association with disorders of GNAS inactivation (Haldeman-Englert et al., 2017); Published functional studies demonstrate a damaging effect (Weinstein et al., 1992; Inta et al., 2014); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29059381, 29072892, 24481334, 21525160, 24626099, 18553568, 15711092, 11784876, 12024004, 9876352, 30729047, 1505964, 20427508, 31793173, 31886927)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:676763</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.4:c.565_568del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_101_20220420054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8992349" SubmissionDate="2024-04-05" DateLastUpdated="2024-04-15" DateCreated="2024-04-15">
        <ClinVarSubmissionID localKey="NM_001077489.4:c.520_523del|OMIM:603233" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004809832" DateUpdated="2024-04-15" DateCreated="2024-04-15" Type="SCV" Version="1" SubmitterName="Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center" OrgID="508075" OrganizationCategory="other" OrgAbbreviation="CGM_KFSHRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-04-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001077489.4:c.520_523del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14359275</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7227096" SubmissionDate="2024-04-19" DateLastUpdated="2024-05-01" DateCreated="2023-04-15">
        <ClinVarSubmissionID localKey="a9192579|MedGen:C0950123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003887548" DateUpdated="2024-05-01" DateCreated="2023-04-15" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1505964</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11784876</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18553568</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20427508</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23796510</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24481334</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24626099</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29059381</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30674755</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30729047</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31793173</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31886927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34254228</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34418133</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34614324</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35296306</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35357904</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35497370</ID>
          </Citation>
          <Comment>The c.565_568delGACT (p.D189Mfs*14) alteration, located in exon 7 (coding exon 7) of the GNAS gene, consists of a deletion of 4 nucleotides from position 565 to 568, causing a translational frameshift with a predicted alternate stop codon after 14 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay._x000D_ _x000D_ Based on the available evidence, the GNAS c.565_568delGACT (p.D189Mfs*14) alteration is classified as pathogenic for pseudohypoparathyroidism and pseudopseudohypoparathyroidism; however, it is unlikely to be causative of McCune-Albright syndrome. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration was detected in the heterozygous state in multiple individuals with pseudohypoparathyroidism or pseudopseudohypoparathyroidism (Chang, 2022; Goode, 2022; Itoh, 2022; Stembridge, 2021; Mendes, 2021; Ozaki, 2021; Crane, 2020; Snanoudj, 2020; Del Monte, 2019; Miyakawa, 2019; Salemi, 2018; Inta, 2014; Schrander, 2014; Elli, 2013; Lebrun, 2010; Adegbite, 2008; Shore, 2002; Weinstein, 1992) Based on the available evidence, this alteration is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.4:c.565_568delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>FinalAVA3AVA4ClinvarDepositThrough031523</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava4_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2694660" SubmissionDate="2020-11-24" DateLastUpdated="2020-07-06" DateCreated="2020-07-06">
        <ClinVarSubmissionID localKey="NM_080425.2:c.2494_2497delGACT|OMIM:603233" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001366579" DateUpdated="2020-07-06" DateCreated="2020-07-06" Type="SCV" Version="2" SubmitterName="Centre for Mendelian Genomics, University Medical Centre Ljubljana" OrgID="505952" OrganizationCategory="clinic" OrgAbbreviation="CMG-UMCL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-02-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM1,PM2,PP5.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_080425.2:c.2494_2497delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8622351</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1194915" SubmissionDate="2017-01-25" DateLastUpdated="2022-10-01" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="NM_000516.5:c.565_568delGACT|OMIM:166350" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000611857" DateUpdated="2022-10-01" DateCreated="2017-09-30" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23796510</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25219572</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NP_000507.1:p.Asp189MetfsTer14</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.5:c.565_568delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0334041" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Abbrev="GeneReviews" Type="review">
          <ID Source="PubMed">29072892</ID>
          <ID Source="BookShelf">NBK459117</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7337346" SubmissionDate="2023-05-01" DateLastUpdated="2023-05-20" DateCreated="2023-05-20">
        <ClinVarSubmissionID localKey="NM_000516.7:c.565_568del" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003925361" DateUpdated="2023-05-20" DateCreated="2023-05-20" Type="SCV" Version="1" SubmitterName="New York Genome Center" OrgID="507558" OrganizationCategory="laboratory" OrgAbbreviation="NYGC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.565_568del p.(Asp189MetfsTer14) variant identified in the GNAS gene has previously been reported in many individuals with Progressive osseous heteroplasia as well as pseudohypoparathyroidism type 1a [PMID: 23796510, 11784876, 20427508, 30729047] and it has been deposited in ClinVar [ClinVarID: 15938] as Pathogenic. The c.565_568del variant is observed in 1 allele (0.0003% MAF with 0 homozygotes) in population databases (gnomAD v2.1.1 and v3.1.2,TOPMed Freeze 8), suggesting it is not a common benign variant in the populations represented in those databases. The c.565_568del p.(Asp189MetfsTer14) variant in the GNAS gene is located in exon 7 of this 13-exon gene, predicted to incorporate a premature termination codon (p.(Asp189MetfsTer14)), and is expected to resultin loss-of-function either through protein truncation or nonsense-mediated mRNA decay. Multiple loss-of-function variants that are downstream to the c.565_568del variant have been reported in the literature [PMID: 20427508, 31886927] in individuals with Progressive osseous heteroplasia or pseudohypoparathyroidism type 1a. Based on available evidence this c.565_568del p.(Asp189MetfsTer14) variant identified in GNAS is classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">NYGC Assertion Criteria 2020</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/hhfhf6ms/nygc_assertion_criteria_2020.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <NamePlatform>NovaSeq 6000</NamePlatform>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">whole genome sequencing</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="NumberMosaic" integerValue="0" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">no</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0003077" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0005978" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.7:c.565_568del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612462" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="166350" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13087046</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7680891" SubmissionDate="2023-11-06" DateLastUpdated="2023-11-11" DateCreated="2023-11-11">
        <ClinVarSubmissionID localKey=":Chr.20_57484248_GCTGA_G|Disorders of GNAS Inactivation" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004101287" DateUpdated="2023-11-11" DateCreated="2023-11-11" Type="SCV" Version="1" SubmitterName="Illumina Laboratory Services, Illumina" OrgID="504895" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1505964</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23796510</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35296306</ID>
          </Citation>
          <Comment>The GNAS c.565_568del (p.Asp189MetfsTer14) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. This variant has been identified in multiple individuals with phenotypes consistent with disorders of GNAS inactivation (PMID: 23796510; 35296306). The c.565_568del variant is not observed in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Functional studies conducted in patient cells demonstrated that this variant leads to reduced mRNA expression (PMID: 1505964). This variant has been classified as pathogenic by multiple submitters in ClinVar. Based on the available evidence, the c.565_568del variant is classified as pathogenic for disorders of GNAS inactivation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ICSLVariantClassificationCriteria RUGD 01 April 2020</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/dy7elfgy/icslvariantclassificationcriteria_rugd_01_april_2020.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="20" alternateAllele="G" referenceAllele="GCTGA" start="57484248" stop="57484252" variantLength="5" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Disorders of GNAS Inactivation</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13955340</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4253734" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="4960702|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002232612" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11784876</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23281139</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23796510</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25802881</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20427508</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Asp189Metfs*14) in the GNAS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNAS are known to be pathogenic (PMID: 11784876, 23281139, 23796510, 25802881). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with GNAS-related conditions (PMID: 20427508). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 15938). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000020.10:g.57484249_57484252del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8837314" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="3589102|GNAS-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004749516" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The GNAS c.565_568delGACT variant is predicted to result in a frameshift and premature protein termination (p.Asp189Metfs*14). This variant has been reported in many unrelated individuals with either progressive osseous heteroplasia (POH) or pseudohypoparathyroidism type 1a (PHP1a) (Lebrun et al. 2010. PubMed ID: 20427508; Salemi et al. 2018. PubMed ID: 29059381; Inta et al. 2014. PubMed ID: 24481334). In several of these patients this variant was found to occur de novo (Lebrun et al. 2010. PubMed ID: 20427508; Crane et al. 2019. PubMed ID: 31793173). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in GNAS are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.5:c.565_568delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GNAS-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="37572" TraitType="Disease" MappingType="Name" MappingValue="PSEUDOHYPOPARATHYROIDISM, TYPE IA" MappingRef="Preferred">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1194915" TraitType="Disease" MappingType="XRef" MappingValue="C0334041" MappingRef="MedGen">
        <MedGen CUI="C0334041" Name="Progressive osseous heteroplasia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="174800" MappingRef="OMIM">
        <MedGen CUI="C0242292" Name="McCune-Albright syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="612463" MappingRef="OMIM">
        <MedGen CUI="C0033835" Name="Pseudopseudohypoparathyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Disease" MappingType="XRef" MappingValue="612462" MappingRef="OMIM">
        <MedGen CUI="C2932716" Name="Pseudohypoparathyroidism type 1C" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="612462" MappingRef="OMIM">
        <MedGen CUI="C2932716" Name="Pseudohypoparathyroidism type 1C" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1569752" TraitType="Disease" MappingType="Name" MappingValue="not specified" MappingRef="Preferred">
        <MedGen CUI="CN169374" Name="not specified" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="166350" MappingRef="OMIM">
        <MedGen CUI="C0334041" Name="Progressive osseous heteroplasia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1945579" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2694660" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="617686" MappingRef="OMIM">
        <MedGen CUI="C4540135" Name="Pituitary adenoma 3, multiple types" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4890417" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8837314" TraitType="Disease" MappingType="Name" MappingValue="GNAS-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="GNAS-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Disease" MappingType="XRef" MappingValue="166350" MappingRef="OMIM">
        <MedGen CUI="C0334041" Name="Progressive osseous heteroplasia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4253734" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="37574" TraitType="Disease" MappingType="Name" MappingValue="PSEUDOPSEUDOHYPOPARATHYROIDISM" MappingRef="Alternate">
        <MedGen CUI="C0033835" Name="Pseudopseudohypoparathyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7227096" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Finding" MappingType="XRef" MappingValue="HP:0005978" MappingRef="HP">
        <MedGen CUI="C0011860" Name="Type 2 diabetes mellitus" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7680891" TraitType="Disease" MappingType="Name" MappingValue="Disorders of GNAS Inactivation" MappingRef="Preferred">
        <MedGen CUI="None" Name="Disorders of GNAS Inactivation" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3099413" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="37573" TraitType="Disease" MappingType="Name" MappingValue="OSSEOUS HETEROPLASIA, PROGRESSIVE" MappingRef="Alternate">
        <MedGen CUI="C0334041" Name="Progressive osseous heteroplasia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8992349" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5457220" TraitType="Disease" MappingType="XRef" MappingValue="219080" MappingRef="OMIM">
        <MedGen CUI="C1857451" Name="ACTH-independent macronodular adrenal hyperplasia 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337346" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003077" MappingRef="HP">
        <MedGen CUI="C0020473" Name="Hyperlipidemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

